Antinatal vaccinations
Pregnancy-related vaccinations may protect both the expectant mother and the unborn child from antibody-preventable illnesses. Due to the fact that their immune system has not fully developed, newborns are at a significant risk of suffering from severe illnesses and dying from some fatal diseases. One goal of immunizing expectant mothers is to increase the amount of maternal counteracting agents—proteins that fight disease—transmitted to the unborn child, potentially protecting them from unstoppable infection.
Related Conference of Antinatal vaccinations
March 24-25, 2026
9th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
Antinatal vaccinations Conference Speakers
Recommended Sessions
- The COVID-19 vaccine's next-generation RNA platforms and mRNA
- Adverse reactions to the vaccination
- Antinatal vaccinations
- Conjugated and combination vaccinations
- Creation and development of vaccines
- DNA, RNA & SYNTHETIC VACCINES
- HIV , Malaria & TB vaccines
- rDNA technology in vaccine development
- Recent advances in vaccine development
- Toxoid vaccination
- Vaccine and Vaccination
- Vaccine efficiency and well-being
- Vaccine for infectious illnesses in humans
- Vaccine manufacturing technologies
- Vaccine Research and Clinical trials
- Vaccines against non-traditional illnesses
- VACCINES FOR CANCER
- Zika Virus vaccines
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (Japan)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (Japan)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2025 (Canada)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (Japan)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Germany)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (Japan)
- Antinatal vaccinations - Vaccines Congress-2025 (Canada)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Germany)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Germany)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - Euro Vaccines 2025 (France)
- Childhood Vaccines and Maternal Vaccines - Euro Vaccines 2025 (France)
- Clinical Trials - VACCINES WORLD 2025 (Germany)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Germany)
- Conjugated and combination vaccinations - Vaccines Congress-2025 (Canada)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Germany)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (Japan)
- Creation and development of vaccines - Vaccines Congress-2025 (Canada)
- DNA Vaccines - Euro Vaccines 2025 (France)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2025 (Canada)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Germany)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Germany)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Germany)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (Japan)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Hepatitis Vaccines - Euro Vaccines 2025 (France)
- HIV , Malaria & TB vaccines - Vaccines Congress-2025 (Canada)
- HIV Vaccines - VACCINES WORLD 2025 (Germany)
- HIV/AIDS Vaccines - Euro Vaccines 2025 (France)
- Human Preventive & Therapeutic Vaccines - Euro Vaccines 2025 (France)
- Human Vaccines - Infectious & Non Infectious Diseases - Euro Vaccines 2025 (France)
- Immune Profiling - VACCINES WORLD 2025 (Germany)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunology/Animal Models - Euro Vaccines 2025 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Germany)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (Japan)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Germany)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (Japan)
- Mucosal Vaccines - Euro Vaccines 2025 (France)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (Japan)
- Next-Generation Vaccine Delivery Technologies - Euro Vaccines 2025 (France)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (Japan)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (Japan)
- rDNA technology in vaccine development - Vaccines Congress-2025 (Canada)
- Recent advances in vaccine development - Vaccines Congress-2025 (Canada)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2025 (Canada)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Germany)
- Toxoid vaccination - Vaccines Congress-2025 (Canada)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine Adjuvants - Euro Vaccines 2025 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Germany)
- Vaccine and Vaccination - Vaccines Congress-2025 (Canada)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2025 (Canada)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2025 (Canada)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2025 (Canada)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Germany)
- Vaccine Research & Development - Euro Vaccines 2025 (France)
- Vaccine Research and Clinical trials - Vaccines Congress-2025 (Canada)
- Vaccine Research and Development - VACCINES WORLD 2025 (Germany)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Germany)
- Vaccines against non-traditional illnesses - Vaccines Congress-2025 (Canada)
- Vaccines against Viral and Bacterial Diseases - Euro Vaccines 2025 (France)
- Vaccines Business Development - Euro Vaccines 2025 (France)
- VACCINES FOR CANCER - Vaccines Congress-2025 (Canada)
- Vaccines for Older Adults - Euro Vaccines 2025 (France)
- Vaccines for Respiratory Diseases - Euro Vaccines 2025 (France)
- Vaccines for Vector-borne Diseases - Euro Vaccines 2025 (France)
- Vaccines Safety & Efficacy - Euro Vaccines 2025 (France)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (Japan)
- Veterinary Vaccine - VACCINES WORLD 2025 (Germany)
- Veterinary Vaccines - Euro Vaccines 2025 (France)
- Zika Virus vaccines - Vaccines Congress-2025 (Canada)